Hyperbaric Oxygen Therapy for CFS involves patients breathing almost pure oxygen while in a pressurised chamber.
This means that the body receives more oxygen, with higher levels than normal being carried into tissue, the brain and organs.
HbOT has already been used successfully to treat a variety of medical ailments, from wound healing to decompression sickness.
Several chronic illnesses, such as CFS and ME are exacerbated by inflammation.
Because HbOT reduces inflammation, it may provide some hope of alleviating symptoms for sufferers.
The benefits of Hyperbaric Oxygen Therapy for CFS include:
Please Note: Hyperbaric Oxygen Therapy complements conventional treatments. We do not recommend it as a replacement. If you are unsure, please consult your doctor.
CFS (Chronic Fatigue Syndrome) and ME (Myalgic Encephalomyelitis), are incapacitating illnesses that can leave people feeling worn out, in pain, and unable to undertake the most basic activities.
There is presently no known treatment for these illnesses, which impact millions of individuals globally.
However, according to current studies, Hyperbaric Oxygen Therapy for CFS may provide some hope for sufferers of CFS and ME.
Reducing inflammation in the body is one of the main benefits of Hyperbaric Oxygen Therapy for CFS.
Several chronic illnesses, such as CFS and ME, are significantly exacerbated by inflammation.
Because HbOT reduces inflammation, it can aid in the relief of pain and the enhancement of general health and well-being.
Another advantage for sufferers is HbOT’s capacity to strengthen the immune system.
CFS and ME are frequently associated with immunological dysfunction. HbOT works to strengthen the immune system, reducing the risk of infection and other diseases while also enhancing general health and wellbeing.
In conclusion, the application of HBOT in the management of ME and CFS is a welcome advance for patients who are affected by these conditions.
The efficacy of Hyperbaric Oxygen Therapy for CFS and ME was investigated in a study published in the Journal of Chronic Fatigue Syndrome. 48 people took part in the trial and received HbOT therapy over a period of eight weeks.
The findings demonstrated that the majority of symptoms including decreased tiredness, enhanced cognitive function, and decreased pain, significantly improved.
What’s more, a significant number of patients in the trial reported that their symptoms had continued to improve six months after the Hyperbaric Oxygen Therapy for CFS had ceased.
This indicates that the benefits of HbOT as an alternative therapy were long-lasting.
Participants in the study tolerated HbOT well, with no significant side effects noted.
This points to the safety and efficacy of HbOT, which is a crucial factor for people considering it as a therapy option.
The findings of the trial point to Hyperbaric Oxygen Therapy for CFS as a potentially beneficial, safe, and long-lasting therapy option. The results give CFS and ME patients who are battling these debilitating conditions, hopeful news that it may provide a long term cure.
Further research is required to completely understand the advantages of HbOT in the treatment of these disorders.
If you are thinking about Hyperbaric Oxygen Therapy for CFS as a therapeutic possibility, contact our friendly team to discuss your options.
HbOT may provide a fresh lease of life if you have CFS or ME, thanks to its capacity to lower inflammation, strengthen the immune system, and encourage recovery.
At Oxify, we look after clients with a range of different health conditions, so we understand the debilitating nature of illnesses like CFS and ME.
Our team will explain the process and ensure your comfort while you undergo treatment in the chamber.
We will explain everything fully and take good care of you whilst you attend one of our centres in Leeds, Manchester, Retford, York or Newcastle/Gateshead.
If you or a loved one would like to know more about Hyperbaric Oxygen Therapy for CFS and how it can help to alleviate your symptoms, please complete our contact form and we will contact you.